Molecule to Market: Inside the outsourcing space
Molecule to Market takes you inside the global pharma and biopharma outsourcing ecosystem. Each week, our host Raman Sehgal sits down with the founders, entrepreneurs, CEOs and C-suite leaders shaping the pharma services and tools that power discovery, drug development and commercialization. Listeners get real stories and practical insights from across the entire value chain, from big pharma and emerging biotechs to private equity investors, CROs, CDMOs, technology platforms and specialist consulting firms. Our host Raman is an entrepreneur, investor, bestselling author, speaker and long time industry insider. https://moleculetomarketpod.com
The CSO Staying Ahead of the CDMO Curve
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Stefan Randl, Chief Scientific Officer at Siegfried.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Stefan, covering:
Â
How his love of science, combined with a desire to get closer to the business, led him to leave Novartis His move from science into commercial roles, and how geographic relocations created a compound impact on his career The decision to leave a large pharma environment and join a smaller CDMO...Leading a State Owned CDMO
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Erik Haeffler, CEO at APL.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Erik, covering:
Two decades at AstraZeneca, including being at the forefront of global sourcing and increasingly sophisticated supply chain management in pharma Managing a highly complex network of more than 100 CDMOs during his time at Meda Lessons from six years at Recipharm, where he led 4,000 people across 14 manufacturing sites The unique story behind APL, what attracted him...CDMO Live Europe: When Outsourcing Goes Wrong 2026
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with:
Â
Oksana Vodovska, Business Development of Sopharma Stefan Bouckaert, Quality & Operations Leader, Enabling Business Growth Nick Wark, Sr. Director / Head of Global External Manufacturing Network, CDMO & Strategic Partnerships, Ferring PharmaceuticalsÂ
Your host, Raman Sehgal, discusses the state of contract manufacturing with his guests live from CDMO Live Europe 2026. The event was hosted by PharmaSource and Molecule to Market.
Â
Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Le...
From the Army Commander to the CDMO Corner Office
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Denis Johnson, Chief Executive Officer at Grand River Aseptic Manufacturing.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Denis, covering:
What his time in the military and the CDMO industry have in common Why he is passionate about operations, and why operational excellence is the real product CDMOs deliver His decision to leave a successful leadership role at Catalent and move to the customer side of the industry Realising his...From Family Pharma to Global injectables CDMO
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Kimberlee Steele, Chief Commercial Officer at ROIS and Javier LĂłpez-Belmonte, Vice Chairman of the Board at ROVI and CEO at ROIS.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kimberlee and Javier, covering:
Â
Kimberleeâs 12 golden years at Catalent, and the lessons she learned during a period of significant CDMO growth The family heritage behind ROVI and its journey to becoming a $4bn market cap global pharmac...Meet the Supply Chain Wizard
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Evren Ozkaya is the Founder & CEO of Supply Chain Wizard and SCW.AI.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Evren, covering:
Â
The job offer that pulled him away from the McKinsey fast track and into the pharma industry Getting hands on experience at Sandoz, delivering real impact before spotting the opportunity to found his own business The moment that triggered the shift from consulting to tech...Building a Canadian CDMO from grad school
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Lisa Studnicki Hunt, Ph.D, Co-Founder and Board Member, GL CHEMTEC.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lisa, covering:
Â
How her passion for problem solving led her to cofound a CDMO straight out of grad school How, without an established industry network, she focused on developing her core skill set and immersing herself in a different culture Figuring things out day by day, while pursuing oppo...From Big Pharma to Biotech CEO
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Rachel Sha, CEO at Terrestrial Bio.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with Rachel, covering:
Navigating the Genzyme Sanofi acquisition and building a leadership career on the other side of the transaction Being in the right place at the right time to pursue entrepreneurship, and the steep learning curve of stepping into a biotech CEO role The decision to adopt a dual strategy, partnering with biopharma on a platform tec...From Lab to Boardroom at Sartorius
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with RenĂŠ, covering:
Â
How a lucky break brought him to Sartorius over 20 years ago, and what has changed and stayed the same over that time His journey from scientist to senior leader, and the evolution of biologics he has witnessed along the way The pace of innovation in bioprocessing, and how he thinks about speed, efficiency and flexibility Why innovation continues regardless of market cycles, through both boom and correction periods His perspective on the current biotech market reset and why it represents a healthy co...CDMO Live Europe: State of Contract Manufacturing 2026
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with:
Â
Kaan-Fabian Kekec, Partner Simon Kucher Kurt Nielson, President, Longview Leader Melanie Wamsler, External Network Strategy Lead, Takeda Rocco Paracchini, Vice President, MorphoÂ
Your host, Raman Sehgal, discusses the state of contract manufacturing with his guests live from CDMO Live Europe 2026. The event was hosted by PharmaSource and Molecule to Market,
Â
Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your indus...
Codexis at TIDES - Stereochemistry in RNA Manufacturing: Signal or Noise?
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with:
Â
Fred Fleitz, SVP, CMC and Development Chemistry, Arrowhead Pharmaceuticals Jason Costigan, Head of CMC, Corsera Health Alison Moore, CEO and President, Codexis, Inc. Muthu Kandasamy, VP of Medicinal Chemistry, Wave Life SciencesÂÂ
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from TIDES 2026. The event was hosted by Codexis and Molecule to Market,
Â
Molecule to Market is also sponsored by Bora Pharmaceuticals and suppor...
Navigating global supply chains at Big Pharma
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Daniel Hurni, Supply Chain Enterprise Capability Lead at Roche.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dan, covering:
Â
Why working all over the world was a key competent in building his confidence, and his understanding of people and perspectives from different cultures. The value of doing an MBA as a technician, and the need to master yourself and becoming the boss of yourself before leading others. A be...Bora Live Panel - The Voice of the Customer
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with:
Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting Firelli Alonso, Founder / Principal Consultant at ConsultFi Biologics LLC Umar Hayat, Founder, CEO at Accanito IncÂ
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from Bora Nexus 2026. The event was hosted by Bora Pharmaceuticals and Molecule to Market,
Â
Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your...
The Making of a CGT CDMO Builder
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Steve Favaloro, Chairman and CEO of Genezen.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steve, covering:
His deep passion for operations, and how early lessons in hard work and customer service shaped his leadership Learning from Mark Bamforth and the entrepreneurial journey at Brammer Bio, culminating in a $1.7bn exit to Thermo Fisher Why gaining exposure to every seat at the table was critical in...
Inside the mind of the CMO outsourcer
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Felipe Furiati, Senior Director, External Supply Operations at GrĂźnenthal.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Felipe, covering:
Â
Why he stepped away from big pharma to pursue an MBA in the US and transition into top tier management consulting, broadening his global perspective The pace and intensity of his time at Bain, and how it expanded his problem solving toolkit across industries The challenges, risks and o...The unconventional CEO
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Tim Dietlin, Chief Executive Officer of ELIQUENT Life Science.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:
Â
Practical advice on the mindset required when navigating M&A from both sides Why he made the move from management consulting into executive search, and why it proved to be the right call How the hunter became the hunted when private equity firm GHO Capital came knocking to take...The Indiana boy driving CGT development
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Sean Werner, Chief Technology Officer at BioLife Solutions,
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sean, covering:
Â
The value of learning your craft in big pharma, and the steep transition from technical expert to President of a spinout Why BioLife moved from board involvement to acquiring Seanâs company outright The critical role of cryopreservation, and why it remains an overlooked risk in cell therapy development His pe...DCAT Live - Morgan Stanley CDMO CEO Dinner
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Alessandro Maselli, President and Chief Executive Officer at Catalent and Franco Negron is the Chief Executive Officer at Simtra BioPharma Solutions.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his esteemed guests during a live fireside chat at the DCAT Morgan Stanley CDMO CEO Dinner.
Â
Alessandro Maselli is the President and Chief Executive Officer of Catalent, having assumed the CEO role in July 2022 after serving as the comp...
DCAT Live Panel - Stick or Twist with Capacity in Times of Uncertainty
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with:
Jake Behrman, 3i Dirk Lange, Pyramid Pharma Hanns-Christian Mahler, ten23 J.D. Mowery, AST/Engage Sarah Stevens, ChrysalisÂ
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from DCAT 2026. The event was hosted by Lead Candidate and sponsored by 3i private equity... and Molecule to Market,
Â
Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry coll...
DCAT Live Panel - Stick or Twist with Capacity in Times of Uncertainty
Â
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with:
Jake Behrman, 3i Dirk Lange, Pyramid Pharma Hanns-Christian Mahler, ten23 J.D. Mowery, AST/Engage Sarah Stevens, ChrysalisÂ
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests live from DCAT 2026. The event was hosted by Lead Candidate and sponsored by 3i private equity... and Molecule to Market,
Â
Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your...
From consulting stay at home dad to global CRO CEO
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Greg Plunkett, Founder and CEO of Accelagen.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Greg, covering:
How years at big pharma exposed him to the full journey from concept to commercialisation. Why stepping into a smaller organisation gave him the practical tools and confidence to start his own venture. How following market signals into regulatory consulting, while being a stay at home dad, became the foundation for Accelagen. Why trust, re...From big pharma manufacturing lead to CDMO CEO
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Joerg Ahlgrimm, CEO SK pharmteco.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Joerg, covering:
Â
His journey from East Germany to leading global manufacturing organisations. How building and integrating acquired CDMO relationships ultimately led him to Lonza, where he helped scale the manufacturing network from fifteen to thirty five sites worldwide. What he learned about the âstickyâ nature of the CDMO business, and the unforgiving reality of being a...M2M Pulse: 7 Trends CDMO You Canât Ignore
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with 20+ CEO and C-suite leaders from the CDMO ecosystem, exploring the overlooked trends for 2026.
Â
Nick Fortin, CEO, Codis Ankit Gupta, CEO, InstaPill Eric Edwards, MD, PhD, CEO, Phlow USA Dirk T. Lange, CEO, Pyramid Pharma Services Kaan-Fabian Kekec, Partner, Simon-Kucher Healthcare and Life Sciences J.D. Mowery, President, CDMO Division, Bora Pharmaceuticals Matthew Bio, CSO, Cambrex and President, Snapdragon Chemistry Bill Vincent, Biotech Entrepreneur, CEO and Board Member Philip Macnabb, CEO, Curia Christiane Bardroff, COO Leader Jas...25+ years & 200+ deals - meet the prolific pharma dealmaker
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Banks Bourne, Founder & Chief Executive Officer at Bourne Partners.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Banks, covering:
Â
How making a bet in the right place at the right time sparked an extraordinary journey in pharma investing. The founding of Bourne Partners and a twenty five plus year ride through multiple market cycles. Lessons from hundreds of deals, and why the best investments are often the most...The 30-year, overnight success
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Julian Casciano, President & CEO at eMAX Health.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julian, covering:
Â
How a family tragedy led him into the healthcare and pharmaceutical world. Why corporate life was not for him, but the valuable lessons he learned during his time at KPMG. The turbulent journey with a venture capital partner that ultimately led to an IPO and a successful first exit. How a re...The CDMO CEO Operator Playbook for 2026
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with 20+ CEO and C-suite leaders from the CDMO ecosystem, exploring two simple questions that reveal whatâs really happening inside the building:
Whatâs the biggest internal business challenge for the year ahead?
And whatâs the biggest opportunity inside their business in 2026?
Your host, Raman Sehgal, brings together a punchy set of operator insights spanning commercial readiness, capacity decisions, flawless execution, commercial excellence, and the shift toward deeper partnerships and integrated models.
Show fea...The AI CEO changing pharma from the inside
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Pep Gubau, CEO, CTO & Co-Founder at Aizon.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Pep, covering:
Â
How working out what not to do very early on led to two successful growth and exit stories. Why surrounding yourself with smarter people is essential to learning, scaling, and long term success. How the industryâs underuse of data led to the creation of Aizon, and the challenge of pitchi...CDMO & C-suite headwinds for 2026
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with 20+ CEO/c-suite leaders from the CDMO space, who discuss the big headwinds for the pharmaceutical and biotechnology space for 2026.
Â
Show features:
Christiane Bardroff, Chief Operating Officer (COO) at Rentschler Biopharma SE Philip Macnabb, Chief Executive Officer at Curia Kaan-Fabian Kekec, Partner at Simon-Kucherâs Healthcare & Life Sciences division Dirk T. Lange , Chief Executive Officer at Pyramid Pharma Services Bruce Thompson, CTO at Kincell Bio Bill Vincent, Biotech Entrepreneur, CEO, Board Member Derek Hennecke - fou...Insights from JPM
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with three senior leaders that attended The JPM's Annual Healthcare Conference 2026:
Chris Garabedian, CEO, Xontogeny and Portfolio Manager, PXV Fund Dean McAlister, Executive Vice President, Inizio Biotech Catherine Hunter, Head of Business Development at ramarketingÂ
Hear from experts who have seen multiple cycles and know the difference between noise and signal.We talk real confidence levels, what actually dominated conversations in San Francisco, where capital and opportunity are genuinely moving.
Molecule to M...
CDMO C-suite optimism pulse for 2026
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with 20+ CEO/c-suite leaders from the CDMO space, who discuss the optimism levels for the pharmaceutical and biotechnology space for 2026.
Â
Guests include:
Christiane Bardroff, Chief Operating Officer (COO) at Rentschler Biopharma SE Philip Macnabb, Chief Executive Officer at Curia Kaan-Fabian Kekec, Partner at Simon-Kucherâs Healthcare & Life Sciences division Dirk T. Lange , Chief Executive Officer at Pyramid Pharma Services Bruce Thompson, CTO at Kincell Bio Bill Vincent, Biotech Entrepreneur, CEO, Board Member Derek Hennecke - fou...The AI entrepreneur fighting against cancer
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Selin Kurnaz, Co-Founder and CEO at Massive Bio,
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Selin, covering:
Â
How a cancer diagnosis in her family led Selin down a path of accidental entrepreneurship, fundraising, and the application of AI in drug development. The major pivots in Massive Bioâs journey that transformed it into a broker of access between patients and pharmaceutical companies. Her views on the misallo...25+ years as pharma-focused PE fund
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Jim Gale, Founding Partner & Managing Director at Signet.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering:
The origins of growth equity in private equity and how it led to the founding of Signet, a fund built on deep domain expertise. Why private equity is a growing asset category but still remains undervalued and under appreciated. How the nature of the companies Signet invests in has evolved over the...2025 Unwrapped: Top 5 Episodes
As we draw close to the end of 2025, our host Raman Sehgal talks about the top 5 episodes of the year.
Â
Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. Weâd also appreciate a positive rating!
Doctor Entrepreneur who pulled off a $1.4b exit
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Thomas Dobmeyer, medical, entrepreneur and investor at ekwithree.
Â
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:
Choosing to freelance and consult as a medic after qualifying in medicine. Co-founding a niche regulatory affairs firm and growing it into a 3,000-person multinational pharmaceutical solutions organisation. Expanding into new countries, acquisitions, and domains to build scale and credibility in biopharma â with culture as the secret weapon. Why lawmakers and regul...M2M Monitor Special - 2026
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with our host Raman Sehgal. Raman distils dozens of executive conversations across 2025 into three key insights you can take into 2026 for you and your organization.Â
Â
Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. Weâd also appreciate a positive rating!
The master building CEO leading Codis
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Nick Fortin, Chief Executive Officer at Codis.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Nick, covering:
Nickâs desire to scratch that entrepreneurial itch, while recognising he was missing a key tool in his toolbox, which led him to pursue a midlife MBA. His turnaround role at Neopharma exposed him to major players in the pharma services space, ultimately paving the way to Particle Dynamics (now Codis). The major pillars Nick...From R&D to CRO CEO
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Dr. Fozia Saleem, Chief Executive Officer at Magnitude Biosciences.
Your host, Raman Sehgal, speaks with Fozia about the pharmaceutical and biotechnology supply chain, including:
How her early roles shaped her focus on applying science and innovation in a practical way The contrast between working in tobacco and vape R&D and traditional pharma research How a post-COVID reckoning led her to a CEO role at a university spin-out The commercial potential of worms, the WormGazerÂŽ tec...M&A Roundtable Q4 2025 â Reflections and Predictions
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with:
Andrew Gigax, Head of European Pharma Services M&A at William Blair Jennifer Chadwick, Founder and Principal at Jennifer Chadwick Consulting Sabina Ouimet Storrs, Principal at GHO Capital Partners Jason Foss, Head of Corporate Development at Bora PharmaceuticalsYour host, Raman Sehgal, speaks with his guests about the pharmaceutical and biotechnology ecosystem, including:
How market stabilisation has been overtaken by the need for adaptation in times of uncertainty Disciplined and deeper M&A, with heightened sc...From Pharma to CRO entrepreneur
In this episode of Molecule to Market, your host Raman Sehgal discusses the pharmaceutical and biotechnology supply chain with Jean-François Brepson, Chief Executive Officer at PathoQuest.
The conversation covers:
Navigating 20 years of global leadership roles at Ipsen before moving from the corporate world into an investor-led entrepreneurial adventure The tough decision to refocus PathoQuest from diagnostics into a pure play CRO and pharma services business How a major strategic partnership transformed the companyâs trajectory and why Jean sees partnerships as a competitive weapon Riding the tailwind of the FDAâs move away from animal testi...The CEO leading Ensera's evolution
In this episode of Molecule to Market, youâll go inside the outsourcing space of the global drug development sector with Jason Anderson, Chief Executive Officer at Ensera.
Â
Your host, Raman Sehgal, speaks with Jason about the pharmaceutical and biotechnology supply chain, covering:
Why he chose BASF over law school, and why McKinsey ultimately was not for him Moving from corporate life into a venture-backed polymer technology start-up before a major exit The search for a PE-backed specialty manufacturing role that led him to Ensera (formerly SteriPack) The importance of appreciating local knowledge when ent...